Instructions for Salticasone (fluticasone, salmeterol)
ATX code: R03AK06 (Salmeterol and fluticasone)
Active substances
fluticasone (fluticasone) Rec.INN recorded by WHO
salmeterol (salmeterol)
Dosed Powder D / Inhaled
The form of release, packaging and composition of the drug Salticasone®
Inhalation powder dosed white or almost white color.
1 dose
salmeterol xinafoate 72.5 ug,
which corresponds to salmeterol content 50 ug
fluticasone propionate 100 ug
Auxiliary substances Salticasone:
sodium benzoate - 2 mg, lactose monohydrate - up to 12 mg.
Inhalation capsules solid gelatin capsules*, size No. 3, body white, cap white.
The composition of the capsule body*: titanium dioxide - 2%, gelatin - up to 100%.
The composition of the capsule cap*: titanium dioxide - 2%, gelatin - up to 100%.
The multi-dose inhaler is a round plastic device with a dose counter; inside the inhaler is one blister with 60 filled cells; the contents of the cells are white or almost white powder.
60 pcs. (60 doses) - packagings, contiguous in the inhaler (OstreaHaler inhaler) (1) - containers/packages of combined material - cardboard packs.
Pharmacotherapeutic group Salticasone:
Combined bronchodilating agent (beta2-adrenomytic selective + local glucocorticosteroid)
ICD-10 Code Indication
J44 Other chronic obstructive pulmonary disease
J45 Asthma
Pharmachologic effect Salticasone
The preparation comprises two active components, namely salmeterol and fluticasone propionate, each of which has pharmacological properties and mechanisms of action.
Salmeterol is a selective long-acting agonist of β2-adrenergic receptors. It prevents symptoms of bronchospasm by stimulating β2-adrenergic receptors in the bronchial smooth muscles and relaxing them. Long-acting salmeterol (up to 12 hours) provides greater protection against histamine-induced bronchoconstriction and longer bronchodilation than short-acting β2 agonists.
In addition, salmeterol is a potent inhibitor of the release of mast cell mediators such as histamine, leukotrienes, and prostaglandin D2 from human lungs. It also suppresses the early and late phases of the response to inhaled allergens, which may help reduce hyperreactivity of the bronchial tree.
Fluticasone propionate is a corticosteroid (GCS) that is given topically and inhaled. At recommended doses, it has anti-inflammatory and anti-allergic effects in the lungs. Fluticasone reduces inflammation in the bronchi and decreases the secretion of inflammatory mediators such as histamine, leukotrienes, and cytokines. As a result, symptomatic relief is reduced, and the incidence of asthma exacerbations is reduced.
The combined drug, containing salmeterol and fluticasone propionate, has a synergistic effect, allowing more effective control of asthma, improving pulmonary function and preventing exacerbations.
How to Accept Salticasone
In doing so, strict adherence to the instructions for use appropriate to the dosage form and dosing regimen used. The drug is used only as an inhaler, and the dose and regimen are adjusted individually based on the patient’s age, the formulation used, and the inhaler.
Indications Salticasone
- of active Salticasone® for regular asthma treatment when long-acting beta2-agonists and inhaled HCS are used as combination therapy include
- Asthma requiring use of a combination of long-acting beta2-agonists and inhaled HCS.
- Bronchial asthma with severe symptoms that are not treated with regular bronchodilators.
- For maintenance therapy, patients with chronic obstructive pulmonary disease (COPD) and an FEV1 (forced expiratory volume in the first second) less than 60% of normal before
- airway inhalation and with a history of recurrent exacerbations who continue to have significant symptoms despite regular bronchodilator therapy.